Who
Joshua A. Kazam
Director
Company insider
Files Form 4 as: Director, Allogene Therapeutics; Director, Kronos Bio; Other, Latch; Director, Tishman Speyer Innovation Corp. II; Director, Diamond Eagle Acquisition Corp. \ DE; Director, Target Hospitality; President & CEO, Capricor Therapeutics; Director, Kite Pharma.
In numbers
- Trades disclosed
- 110
- Buys
- 13
- Sells
- 0
- Bought
- $331K
- Sold
- $0
- Companies
- 9
- Companies where not an officer
- 8
- First trade
- 24 May 2007
- Last trade
- 18 Jun 2026
- Last filed
- 23 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Jun 2026filed 23 Jun 2026 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Code M | —47,700 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —47,700 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —95,400 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —47,700 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —95,400 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Code M | —47,700 at $0.00 | filing |
| 18 Dec 2025filed 22 Dec 2025 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —47,700 at $0.00 | filing |
| 18 Dec 2025filed 22 Dec 2025 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Code M | —47,700 at $0.00 | filing |
| 20 Jun 2025filed 20 Jun 2025 | Kronos Biooption or derivative | SEC FORM 4 Code D | —20,600 at $0.00 | filing |
| 20 Jun 2025filed 20 Jun 2025 | Kronos Biooption or derivative | SEC FORM 4 Code D | —34,000 at $0.00 | filing |
| 20 Jun 2025filed 20 Jun 2025 | Kronos Biooption or derivative | SEC FORM 4 Code D | —34,000 at $0.00 | filing |
| 20 Jun 2025filed 20 Jun 2025 | Kronos Biooption or derivative | SEC FORM 4 Code D | —34,000 at $0.00 | filing |
| 20 Jun 2025filed 20 Jun 2025 | Kronos Bio | SEC FORM 4 Code U | $54K94,481 at $0.57 | filing |
| 18 Jun 2025filed 23 Jun 2025 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —94,500 at $0.00 | filing |
| 25 Jun 2024filed 26 Jun 2024 | Kronos Biooption or derivative | SEC FORM 4 Code A | —34,000 at $0.00 | filing |
| 5 Jun 2024filed 7 Jun 2024 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —191,082 at $0.00 | filing |
| 22 Jun 2023filed 26 Jun 2023 | Kronos Biooption or derivative | SEC FORM 4 Code A | —34,000 at $0.00 | filing |
| 13 Jun 2023filed 15 Jun 2023 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —116,120 at $0.00 | filing |
| 22 Jun 2022filed 29 Jun 2022 | Kronos Biooption or derivative | SEC FORM 4 Code A | —34,000 at $0.00 | filing |
| 15 Jun 2022filed 17 Jun 2022 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Code A | —44,178 at $0.00 | filing |
News
Head to Head Analysis: Keros Therapeutics (NASDAQ:KROS) & Allogene Therapeutics (NASDAQ:ALLO)ALLO · tickerreport.com · 24 Oct 2026Comparing eXoZymes (NASDAQ:EXOZ) and Allogene Therapeutics (NASDAQ:ALLO)ALLO · dailypolitical.com · 16 Oct 2026
0 headlines in the last 90 days name Joshua A. Kazam; 2 articles from the last 14 days about the 3 companies they traded most, at most three about any one of them.